INOVIQ Limited (ASX:IIQ) has been granted US Patent 11,193,944 titled ‘Kits for detecting breast or ovarian cancer in a body fluid sample and use thereof’ by the United States Patent and Trademark Office (USPTO).
The issued US Patent 11,193,944 is a continuation of US 10,018,639 with additional claims directed towards a method for detecting BARD1 autoantibodies associated with breast or ovarian cancer in body fluids and related assays, kits and peptides.
The patent application was filed by INOVIQ Ltd (previously BARD1 Life Sciences Limited) on June 13, 2018 and is due to expire on 28 November 28, 2032.
There is an important unmet medical need for non-invasive, accurate and reliable tests for earlier detection and monitoring of breast and ovarian cancers to improve women’s health outcomes,” CEO Dr Leearne Hinch said.
“This patent provides IP protection for potential BARD1 autoantibody tests for detection of breast and ovarian cancer in the USA.”
This BARD1 patent family now has three granted patents enforcing protection in the key US and European markets.
INOVIQ Ltd is developing and commercialising an innovative portfolio of diagnostic and exosome-based products to improve the diagnosis and treatment of cancer and other diseases.
The company has commercialised the hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NET pan-exosome capture tool for research purposes. Its cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast, prostate, and other cancers.
